Legal action against GSK over SSRI data
- 6 July 2004
- journal article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 171 (1) , 23
- https://doi.org/10.1503/cmaj.1040982
Abstract
The case arose after a confidential GSK memo leaked to media (CMAJ 2004;170[5]:783) documented a 1998 clinical trial that concluded paroxetine had no beneficial effect in the treatment of adolescents. The authors of the report recommended GSK “effectively manage the dissemination of these data in order to minimize any potential negative commercial impact.” Sales for paroxetine totalled nearly $4.97 billion worldwide in 2003.Keywords
This publication has 0 references indexed in Scilit: